08.01.2013 - US-based Cubist Pharmaceuticals and British Heptares sealed a €7.2m license deal. Cubist pays to snatch a drug candidate for an undisclosed GPCR target.
The small spin-off Heptares Therapeutics from Welwyn Garden City north of London has landed a license deal with US biopharma Cubist Pharmaceuticals, Inc. Heptares’ area of expertise are G-protein coupled receptors (GPCR). Cubist will pay €4.2m up front and €3.1m in research funding plus undisclosed milestone payments and royalties. Heptares, in return, uses its proprietary platform technology to screen for drug candidates targeting an unnamed GPCR specified by Cubist. The deal also includes an option for a second target. Financial details covering that part of the collaboration have been predetermined – but will not be made public. Both parties agreed that the preclinical development will be carried out solely by Cubist.
Heptares was spun off from the Medical Research Council in 2007. The company engineers stabilised GPCRs (so-called STaRs), circumventing the problematic handling of the otherwise labile receptors. The UK firm entered biopharma main stage only last spring when it became eligible to receive payments potentially equalling €145m. Back then Irish Shire plc licensed a Heptares-discovered preclinical antagonist of the GPCR A2A (see photo) which could turn to a new CNS disorders medicine. Also AstraZeneca and Novartis belong to Heptares’ customers.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more